Genpharm is proud to have been an associate sponsor, for the second consecutive year, of the Orphan Drug Meeting Europe, held in Geneva this past week.
In its fourth edition, the meeting was the largest ever assembling more than 350 delegates representing key players in the rare disease and orphan drugs field. This confirms the increased interest in the growing segment of orphan drugs, estimated to grow to $93bio by 2018 at an annual rate of 8%.
Pharmaceutical companies and drug manufacturers, clinical and research organizations, regulators and patient advocacy groups from around the globe, exchanged insightful information on the latest advances in the rare disease sphere. The debate focused on clinical research, regulatory pathways, pricing of orphan drugs and in particular on market access programs for patients suffering from genetic and rare disorders.
The meeting included a workshop on financing as well, focusing on the interests and investment strategies of private equity and venture capitalist groups in funding research of orphan drugs.
Lastly, the Rare and Orphan Advocacy and Research (ROAR) distributed awards to key players in the sector such as for the best CRO and th best Market Access Program.
For more info please check http://www.terrapinn.com/2013/world-orphan-drug-congress/